Clinical Trial Update: Evaluation of a Dose Reduction of Darunavir (400 mg/d) in Virologically Suppressed HIV-1 Patients [Phase 2]

View source ↗

Summary

Phase 2 study evaluating a reduced darunavir dose (400 mg/day) in virologically suppressed HIV-1 patients; the trial has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• HIV Infection

Drugs mentioned

• Darunavir (darunavir)

Snippet

Sponsor: ANRS, Emerging Infectious Diseases | Conditions: HIV INFECTION | Phase 2 | Status: COMPLETED